EQL PHARMA AB Market Cap ($59.21 Million)
Market Cap & Net Worth: EQL PHARMA AB (7JK)
EQL PHARMA AB market cap. EQL PHARMA AB (F:7JK) has a market capitalization of $59.21 Million (€50.64 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #21074 globally and #1898 in its home market, demonstrating a 0.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EQL PHARMA AB's stock price €1.74 by its total outstanding shares 29529610 (29.53 Million). Also see 7JK cash generation efficiency for how efficiently the company converts equity into cash flow.
EQL PHARMA AB Market Cap History (2021–2026)
EQL PHARMA AB market cap history from 2021 to 2026. Data shows change from $124.97 Million to $60.14 Million (-11.94% CAGR). Check EQL PHARMA AB stock price for real-time trading data and today's change.
EQL PHARMA AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EQL PHARMA AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore EQL PHARMA AB equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.14x
EQL PHARMA AB's market cap is 0.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.80x
EQL PHARMA AB's market cap is 4.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $90.80 Million | $409.75 Million | $31.55 Million | 0.22x | 2.88x |
| 2023 | $96.32 Million | $259.91 Million | $30.92 Million | 0.37x | 3.12x |
| 2024 | $234.76 Million | $264.17 Million | $22.70 Million | 0.89x | 10.34x |
| 2025 | $184.35 Million | $373.52 Million | $43.12 Million | 0.49x | 4.28x |
| 2026 | $60.14 Million | $432.66 Million | $12.54 Million | 0.14x | 4.80x |
Competitor Companies of 7JK by Market Capitalization
Companies near EQL PHARMA AB in the global market cap rankings as of November 4, 2026. Also see 7JK current and non-current assets for a full breakdown of the balance sheet.
Key companies related to EQL PHARMA AB by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of EQL PHARMA AB (2021–2026)
Market capitalization of EQL PHARMA AB from 2021 to today. Between 2021 and today, EQL PHARMA AB's market cap moved from $124.97 Million to $ 60.14 Million, with a yearly change of -11.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €60.14 Million | -67.38% |
| 2025 | €184.35 Million | -21.47% |
| 2024 | €234.76 Million | +143.73% |
| 2023 | €96.32 Million | +6.08% |
| 2022 | €90.80 Million | -27.35% |
| 2021 | €124.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of EQL PHARMA AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $59.21 Million USD |
| MoneyControl | $59.21 Million USD |
| MarketWatch | $59.21 Million USD |
| marketcap.company | $59.21 Million USD |
| Reuters | $59.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.